4-(4-benzylpiperazin-1-yl)-1-methyl-3-nitroquinolin-2(1H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-(4-benzylpiperazin-1-yl)-1-methyl-3-nitroquinolin-2(1H)-one
• 英文别名: 4-(4-benzylpiperazin-1-yl)-1-methyl-3-nitroquinolin-2-one
• 化学式: C21H22N4O3
• 分子量: 378.4
• InChiKey: YYIKFTJXOYTLQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  72.6
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
  申请人：Gaeta C.A. Federico

  公开号：US20070232613A1

  公开（公告）日：2007-10-04

  Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R 1 , R 2 , R 3 , R 4 , X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  提供了MIF抑制剂，可用于治疗多种疾病，包括与MIF活性相关的病理条件的治疗。MIF抑制剂具有以下结构：包括立体异构体，前药和其药物可接受的盐，其中n，R1，R2，R3，R4，X，Y和Z的定义如本文所述。还提供了含有MIF抑制剂与药物可接受载体结合的组合物，以及使用它们的方法。
• INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME
  申请人：Gaeta C.A. Federico

  公开号：US20070197547A1

  公开（公告）日：2007-08-23

  Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R 1 , R 2 , R 3 , R 4 , X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  提供了MIF抑制剂，可用于治疗多种疾病，包括与MIF活性相关的病理性状况的治疗。MIF抑制剂具有以下结构：包括立体异构体、前药和其药学上可接受的盐，其中n、R1、R2、R3、R4、X、Y和Z的定义如本文所述。还提供了含有MIF抑制剂与药学上可接受的载体组合的组合物，以及使用它们的方法。
• US7192955B2
  申请人：——

  公开号：US7192955B2

  公开（公告）日：2007-03-20
• US7157469B2
  申请人：——

  公开号：US7157469B2

  公开（公告）日：2007-01-02
• US7192961B2
  申请人：——

  公开号：US7192961B2

  公开（公告）日：2007-03-20